Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer
NCT ID: NCT02869282
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2011-06-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer
NCT00967889
Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer
NCT02279693
PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma
NCT00427817
Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT02040610
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
NCT01961713
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The two main objectives are:
* To describe the variations in expression of chemokines in serum and urine level in patients with prostate cancer
* And to study the disease stage and intra-prostatic concentrations of chemokines based on serum and urine concentrations of chemokines before treatment initiation.
These estimates can be used in future trials set up for the management of prostate cancer
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospective cohort
Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
Blood samples
Additional blood samples at baseline, 6, 12, 18 and 24 months.
Urine samples
Additional urine samples at baseline, 6, 12, 18 and 24 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Additional blood samples at baseline, 6, 12, 18 and 24 months.
Urine samples
Additional urine samples at baseline, 6, 12, 18 and 24 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a detectable PSA (Prostate-Specific Antigen)
* Patients who signed an informed consent
* Patients over 18 years
* Patients belonging to the social security scheme
Exclusion Criteria
* HIV positive
* Patients who have received prior chemotherapy
* Patients with a second neoplasia treated in the last 5 years
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Bergonié
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Bergonié
Bordeaux, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IB2011-CHEMOPROST
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.